|
Company data displayed is for sample purposes only and may not reflect the most current information available on Emerging Markets Information Service (EMIS).
GLAXOSMITHKLINE CONSUMER NIGERIA PLC
Main Activities: Chemical Manufacturing - Pharmaceutical and Medicine Manufacturing
 |
Please check the full coverage of information what EMIS can offer you. | SEE SAMPLE |
Company Information |
|
Full name GLAXOSMITHKLINE CONSUMER NIGERIA PLC Headquarters GSK House No. 1, Industrial Avenue, Ilupeju, Ikeja, Lagos ; Lagos; Lagos |
Status: Listed Legal Form: Other non-liability limited Operational Status: Operational ISIN CODE : NGGLAXOSMTH8 Financial Auditors: PricewaterhouseCoopers (2010) Incorporation Date: July 1, 1979 Total Employees: 439 Tel: +234 1 2711 000 |
|
Company Description |
| GLAXOSMITHKLINE CONSUMER NIGERIA PLC is a subsidiary of GSK group and involved in the manufacturing, marketing and distribution of health product in Nigeria. The product includes treatments for asthma, HIV/AIDS, malaria, depression, migraine, diabetes, heart failure, digestive conditions and cancer. The Company mission is to improve the quality of human life by enabling people to do more, feel better and live longer. The Company was listed in Nigerian Stock Exchange on July 1979. |
Company Analysis |
| According to the Consolidated - Non-Audited financial statement for the Year of 2011, total net operating revenues increased with 24.56%, from NGN 17,297,175 thousands to NGN 21,545,196 thousands. Operating result increased from NGN 3,336,982 thousands to NGN 3,502,787 thousands which means 4.97% change. The results of the period decreased -6.48% reaching NGN 2,302,000 thousands at the end of the period against NGN 2,461,395 thousands last year. Return on equity (Net income/Total equity) went from 29.55% to 25.57%, the Return On Asset (Net income / Total Asset) went from 16.70% to 12.83% and the Net Profit Margin (Net Income/Net Sales) went from 14.23% to 10.68% when compared to the same period of last year. The Debt to Equity Ratio (Total Liabilities/Equity) was 99.23% compared to 76.92% of last year. Finally, the Current Ratio (Current Assets/Current Liabilities) went from 1.53 to 1.19 when compared to the previous year. |
Key Executives |
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
Companies with Similar Main Activities |
FULL COMPANY PROFILE
|
|
2011 Y (cons) |
2010 Y (cons) |
|
 | ||
| Non-Audited | Non-Audited | |
| ||
| WVB Company Financials | WVB Company Financials | |
| ||
| Unit | Thousands | Thousands |
| ||
Balance Sheet
| ||
Total Assets |
17,937,080 |
14,737,912 |
| ||
Current Assets |
10,675,079 |
7,857,202 |
| ||
Total Liabilities |
8,934,000 |
6,407,503 |
| ||
Shareholders Equity |
9,003,079 |
8,330,409 |
| ||
Current Liabilities |
8,934,000 |
5,143,337 |
| ||
| * All the accounts are in NGN. | ||
Income Statement
| ||
Total Operating Revenue |
21,545,196 |
17,297,175 |
| ||
Operational Profit (Loss) |
3,502,787 |
3,336,982 |
| ||
Net Profit (Loss) |
2,302,000 |
2,461,395 |
| ||
| * All the accounts are in NGN. | ||
Ratios
| Profitability Ratios | ||
| ||
Return on Assets (ROA) |
12.83% |
16.7% |
| ||
Annualised Return on Assets (ROA) |
12.83% |
16.7% |
| ||
Return on Equity (ROE) |
25.57% |
29.55% |
| ||
Annualised Return on Equity (ROE) |
25.57% |
29.55% |
| ||
Return on Sales (ROS) |
10.69% |
14.6% |
| ||
Return on Capital |
25.57% |
29.55% |
| ||
Gross Profit Margin |
41.76% |
47.32% |
| ||
Operating Profit Margin |
16.18% |
20.42% |
| Efficiency Ratios | ||
| ||
Accounts Receivable Turnover |
22.99x |
15.83x |
| ||
Inventory Turnover |
2.67x |
2.03x |
| ||
Current asset turnover |
2.02x |
2.15x |
| ||
Fixed-asset turnover |
2.96x |
2.45x |
| ||
Asset Turnover |
1.2x |
1.14x |
| Valuation figures and ratios | ||
| ||
Earning Before Interests and Taxes (EBIT) |
3,503,196 |
3,339,592 |
| ||
EBITDA |
3,503,196 |
3,876,600 |
| ||
Enterprise value |
18,021,127 |
23,747,005 |
| ||
Enterprise Value / EBITDA |
5.14 |
6.13 |
| ||
Bookvalue (BV) |
17,937,080 |
14,737,912 |
| ||
Net Cash |
-4,951,000 |
-4,016,111 |
| Liquidity Ratios | ||
| ||
Current Ratio |
119.49% |
152.76% |
| ||
Quick ratio |
67% |
67.59% |
| ||
Doom's day ratio |
44.58% |
21.92% |
| Leverage Ratios | ||
| ||
Leverage ratio |
199.23% |
176.92% |
| ||
Interest Coverage Ratio |
196,037.83% |
479,826.44% |
| ||
Debt to equity |
99.23% |
76.92% |
| ||
Debt to total assets |
49.81% |
43.48% |
| ||
Long Term Debt to Capital |
0% |
72.55% |
| Market ratios | ||
| ||
Market Capitalization/EBITDA |
6.28 |
6.42 |
| ||
Price/Book Ratio |
1.23 |
1.69 |
| ||
Market Cap / Net cash |
-4.44 |
-6.19 |
| Trend Ratios | ||
| ||
Revenue Trend |
127.64% |
112.78% |
| ||
Net Income Trend |
93.52% |
144.63% |
| ||
Operating Income Trend |
104.9% |
128% |
| ||
 |